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February 1, 2011:634–6In common with transapical series, we found that subclavian
atients were a higher risk cohort than transfemoral patients, with
ignificantly higher average EuroSCORE, more prevalent comor-
idities, and more frequent impairment of left ventricular function.
owever, in contrast to major transapical registries, outcomes of
ubclavian TAVI were at least as good as in the transfemoral
ohort, with 100% procedural success, 0% mortality at 30 days, and
strong trend toward reduced MACCE. The more frequent
ttainment of an “optimal” valve position in the subclavian cohort
ay reflect greater control of the deployment catheter, because the
istance and tortuosity between the access site and valve are
educed.
One other national multicenter experience of 54 subclavian
oreValve TAVI cases has recently been reported, with very
imilar findings (3). Subclavian patients had significantly higher
uroSCORE and an increased incidence of peripheral vascular
isease, coronary artery disease, prior myocardial infarction, and
rior percutaneous coronary intervention than femoral patients.
he 30-day mortality was 0% versus 6.1% in the femoral cohort
p  0.13). “Suboptimal” valve positions were more frequently
bserved in femoral patients.
The findings of this study are limited by the relatively small
umber of subclavian patients, the registry design, and the absence
f independent event adjudication. Nonetheless, the U.K. experi-
nce is consistent with existing data in demonstrating excellent
utcomes with a subclavian approach in patients without suitable
emoral access despite a higher risk profile, supporting the use of
his technique for CoreValve TAVI in these patients. This
ontrasts with reported outcomes of transapical TAVI and raises
he possibility that the subclavian approach may be preferable to
ransapical access in patients with peripheral vascular disease.
We conclude that TAVI via the subclavian artery is a safe and
easible alternative in patients without suitable femoral access.
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2007;50:69–76.Letters to the Editorulticenter Experience
ith Extraction of the
print Fidelis Implantable
ardioverter-Defibrillator Lead
e read with interest the recent multicenter report of the safe
xtraction experience with the Sprint Fidelis lead (Medtronic,
inneapolis, Minnesota) (1). Our single-center experience hasxtractions. We agree with the authors that the time has come to
econsider the recommendations for Fidelis lead management in
ight of this and other data. In addition to the established
elationship between shock frequency and mortality (2), the
orbidity of lead failure in these patients is severe and psycholog-
cally long-lasting, often leading to significant disability (3); this,
oupled with the recently reported exponential increase in Fidelis
ead failures over time, suggests that routine advice at the time of
ulse generator replacement should now be to electively remove all
ormally functioning Fidelis leads (4). Because the risk of system
nfection is assumed by opening the pocket to replace the pulse
enerator, there is essentially no additional risk except that related
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636 Correspondence JACC Vol. 57, No. 5, 2011
February 1, 2011:634–6o the extraction, which in highly experienced hands has now been
hown to be minimal. It is now our practice in patients undergoing
ulse generator replacement who require ongoing defibrillator
herapy and who do not have substantial life-limiting comorbidi-
ies to recommend removal and replacement of the Fidelis lead
ecause later removal after lead failure is more likely to be difficult
nd associated with a higher risk of complications (1). We agree
ith the editorialists regarding the need to offer individualized
dvice regarding lead management (5), but we believe that the
nus has now shifted in favor of routine extraction, and failure to
emove this potentially dangerous lead in individual patients under-
oing pulse generator replacement should now be the exception and
ot the rule. Optimal patient care mandates that such patients be
eferred to experienced centers for extraction, and this condition
hould be a fundamental feature of any revised guidelines.
David T. Martin, MD
ruce G. Hook, MD
. Muqtada Chaudhry, MD
onathan Silver, MD
Cardiac Arrhythmia Service
epartment of Cardiovascular Medicine
ahey Clinic Medical Center
1 Mall Road
urlington, Massachusetts 01805
-mail: david.t.martin@lahey.org
doi:10.1016/j.jacc.2010.09.035
EFERENCES
. Maytin M, Love CJ, Fischer A, et al. Multicenter experience with
extraction of the Sprint Fidelis implantable cardioverter-defibrillator
lead. J Am Coll Cardiol 2010;56:646–50.
. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable
cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms,
predictors, and survival impact. J Am Coll Cardiol 2008;51:1357–65.
. Sears SF, Matchett M, Conti JB. Effective management of ICD patient
psychosocial issues and patient critical events. J Cardiovasc Electro-
physiol 2009;20:1297–304.
. Faulknier BA, Traub DM, Aktas MK, et al. Time-dependent risk of
Fidelis lead failure. Am J Cardiol 2010;105:95–9.
. Maisel WH, Kramer DB. Extracting guidance from extraction data.
J Am Coll Cardiol 2010;56:651–2.
eply
e thank Dr. Martin and colleagues for their interest in our paper
1) and commend the authors on their similarly successful experi-
nce with transvenous lead extraction (TLE) of the Medtronic
print Fidelis implantable cardioverter-defibrillator (ICD) lead
Medtronic, Minneapolis, Minnesota). Their reported success
llustrates that TLE of the Sprint Fidelis ICD lead can be a safe
rocedure in select patients and experienced hands.Furthermore, we appreciate the authors’ support of our conten-
ion that in select patients and experienced hands, the current
ecommendations regarding Sprint Fidelis ICD lead extraction
arrant reconsideration. In fact, our practice regarding the man-
gement of the Sprint Fidelis lead at the time of pulse generator
eplacement is similar to that described by the authors; among
atients undergoing pulse generator replacement “who require
ngoing defibrillator therapy and who do not have substantial
ife-limiting comorbidities,” we offer TLE after a frank discussion
egarding the risks and benefits of all potential management
trategies for the Sprint Fidelis ICD lead, including continued
onitoring, lead revision, and extraction with lead replacement.
lthough concerns regarding potential future lead failure certainly
nter the equation, our rationale for this approach is primarily
riven by the significant increasing need for countertraction sheath
ssistance with each additional month of implant duration (1),
mplying more difficulty and potentially more risk with TLE of the
print Fidelis ICD lead over time.
We remain steadfast in our assertion that decisions regarding
xtraction of the Sprint Fidelis ICD lead must be made on a
ase-by-case basis considering multiple patient- and physician-
elated variables because TLE has the potential for significant
orbidity and mortality and may not be warranted in patients with
poor prognosis or where the risks of intervention clearly outweigh
he benefits. Moreover, we reiterate that lead extractions should
ot be performed by those inexperienced in the procedure, by those
ithout the necessary tools available to attain complete success, or
n a setting not prepared and committed to the complete and safe
erformance of the procedure.
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